KR20100016462A - 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도 - Google Patents

변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도 Download PDF

Info

Publication number
KR20100016462A
KR20100016462A KR1020097023568A KR20097023568A KR20100016462A KR 20100016462 A KR20100016462 A KR 20100016462A KR 1020097023568 A KR1020097023568 A KR 1020097023568A KR 20097023568 A KR20097023568 A KR 20097023568A KR 20100016462 A KR20100016462 A KR 20100016462A
Authority
KR
South Korea
Prior art keywords
polypeptide
fvii polypeptide
fvii
modified fvii
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020097023568A
Other languages
English (en)
Korean (ko)
Inventor
에드윈 엘. 매디슨
크리스토퍼 디. 타노스
산드라 와프 러글스
숀 코플린
Original Assignee
카탈리스트 바이오사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카탈리스트 바이오사이언시즈, 인코포레이티드 filed Critical 카탈리스트 바이오사이언시즈, 인코포레이티드
Publication of KR20100016462A publication Critical patent/KR20100016462A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
KR1020097023568A 2007-04-13 2008-04-11 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도 Abandoned KR20100016462A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92351207P 2007-04-13 2007-04-13
US60/923,512 2007-04-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157014839A Division KR20150067772A (ko) 2007-04-13 2008-04-11 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20100016462A true KR20100016462A (ko) 2010-02-12

Family

ID=39689319

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097023568A Abandoned KR20100016462A (ko) 2007-04-13 2008-04-11 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도
KR1020157014839A Ceased KR20150067772A (ko) 2007-04-13 2008-04-11 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157014839A Ceased KR20150067772A (ko) 2007-04-13 2008-04-11 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도

Country Status (29)

Country Link
US (1) US20100166729A9 (enExample)
EP (2) EP2481797A1 (enExample)
JP (3) JP5761782B2 (enExample)
KR (2) KR20100016462A (enExample)
CN (2) CN101743309B (enExample)
AU (1) AU2008239586B2 (enExample)
BR (1) BRPI0810172A2 (enExample)
CA (1) CA2683443A1 (enExample)
CO (1) CO6231052A2 (enExample)
CR (1) CR11058A (enExample)
DK (1) DK2147096T3 (enExample)
EC (1) ECSP099735A (enExample)
ES (1) ES2537328T3 (enExample)
GT (1) GT200900268A (enExample)
HN (1) HN2009002098A (enExample)
IL (2) IL201173A0 (enExample)
MX (1) MX2009010997A (enExample)
NI (1) NI200900187A (enExample)
NZ (2) NZ593611A (enExample)
PH (1) PH12014501960A1 (enExample)
PL (1) PL2147096T3 (enExample)
PT (1) PT2147096E (enExample)
RU (1) RU2571931C2 (enExample)
SG (1) SG174077A1 (enExample)
SI (1) SI2147096T1 (enExample)
SV (1) SV2009003393A (enExample)
UA (1) UA101155C2 (enExample)
WO (1) WO2008127702A2 (enExample)
ZA (2) ZA200906854B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
JP5376747B2 (ja) * 2002-10-02 2013-12-25 カタリスト バイオサイエンシーズ， インコーポレイテッド 改変された特異性を有するプロテアーゼを作製する方法およびスクリーニングする方法
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
WO2005110453A2 (en) * 2004-04-12 2005-11-24 Catalyst Biosciences, Inc. Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
ES2611608T3 (es) * 2005-10-21 2017-05-09 Catalyst Biosciences, Inc. Proteasas modificadas que inhiben la activación del complemento
US8383388B2 (en) * 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
TWI369402B (en) 2006-07-05 2012-08-01 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
BRPI0810172A2 (pt) * 2007-04-13 2014-10-14 Catalyst Biosciences Inc Polipeptídeos de fator vii modificado e seus usos
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP2177624A1 (en) * 2008-10-02 2010-04-21 Siemens Healthcare Diagnostics Products GmbH Blood coagulation assays
WO2010151736A1 (en) 2009-06-25 2010-12-29 The University Of North Carolina At Chapel Hill Chimeric factor vii molecules
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
PL2624859T3 (pl) 2010-10-06 2017-09-29 Medimmune Limited Czynnik ii samodzielnie lub w skojarzeniu z dalszymi czynnikami do leczenia zaburzeń hemostazy powiązanych z koagulopatią z rozcieńczenia
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
TWI595004B (zh) * 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
LT3254703T (lt) 2011-04-22 2020-05-25 The Regents Of The University Of California Adenoasocijuoto viruso virionai su variantine kapside ir jų panaudojimo būdai
WO2012149463A1 (en) * 2011-04-29 2012-11-01 The University Of North Carolina At Chapel Hill Chimeric factor vii molecules with enhanced half life and methods of use
EP2554161A1 (en) 2011-08-02 2013-02-06 LFB Biotechnologies Pharmaceutical composition comprising factor VII encapsulated in micelles
HRP20191920T1 (hr) * 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
EA033469B1 (ru) 2012-04-16 2019-10-31 Cantab Biopharmaceuticals Patents Ltd Подкожное введение конъюгатов факторов крови с полиэтиленгликолем
WO2013177584A2 (en) * 2012-05-25 2013-11-28 The Children's Hospital Of Philadelphia FVIIa VARIANTS EXHIBITING ALTERED INTERACTION WITH ENDOTHELIAL PROTEIN C RECEPTOR (EPCR) AND METHODS OF USE THEREOF FOR MODULATING HEMOSTASIS
WO2014008172A2 (en) * 2012-07-03 2014-01-09 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
WO2014018120A1 (en) 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
CN104661685A (zh) 2012-10-15 2015-05-27 诺和诺德保健Ag（股份有限公司） 因子vii缀合物
EP3524618B1 (en) 2013-03-15 2023-03-08 GLAdiator Biosciences, Inc. Gla domains as targeting agents
WO2014194132A1 (en) 2013-05-31 2014-12-04 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
CN104774269B (zh) * 2013-08-16 2016-02-24 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
BR112016008039A2 (pt) 2013-10-15 2017-10-17 Novo Nordisk Healthcare Ag polipeptídeos do fator vii da coagulação
CN105992816B (zh) 2013-11-16 2018-04-17 泰尔茂比司特公司 生物反应器中的细胞扩增
CA2942776C (en) 2014-03-17 2023-01-24 Adverum Biotechnologies, Inc. Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter
CN106232800B (zh) 2014-03-25 2020-07-03 泰尔茂比司特公司 介质的被动替代
SI3149163T1 (sl) 2014-05-26 2020-10-30 Academisch Ziekenhuis Leiden Prohemostatski proteini za zdravljenje krvavitve
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
KR20170137730A (ko) 2015-03-02 2017-12-13 애드베룸 바이오테크놀로지스, 인코포레이티드 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법
WO2016154344A1 (en) 2015-03-24 2016-09-29 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
KR20230039779A (ko) 2016-07-29 2023-03-21 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 변이체 캡시드를 갖는 아데노-관련된 바이러스 비리온 및 이의 사용 방법
EP3528785A4 (en) 2016-10-19 2020-12-02 Adverum Biotechnologies, Inc. MODIFIED AAV CASPIDS AND USES THEREOF
US12161696B2 (en) 2016-12-02 2024-12-10 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656841A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
WO2018208973A1 (en) * 2017-05-09 2018-11-15 Emory University Clotting factor variants and their use
WO2018222503A1 (en) * 2017-05-31 2018-12-06 The Regents Of The University Of California Adeno-associated virus with variant capsid and methods of use thereof
CN110461368A (zh) 2017-06-30 2019-11-15 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
EP3676373A4 (en) 2017-08-28 2021-06-09 The Regents of The University of California Adeno-associated virus capsid variants and methods of use thereof
AU2018328223A1 (en) 2017-09-05 2020-03-12 GLAdiator Biosciences, Inc. Delivery of payloads to stem cells
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
EP3830273A4 (en) * 2018-08-03 2022-05-18 Duke University PROTEIN C FACTOR VII CHIMERAS
EP3833381B1 (en) * 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
EP4314244B1 (en) 2021-03-23 2025-07-23 Terumo BCT, Inc. Cell capture and expansion
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
WO2024228958A2 (en) * 2023-05-04 2024-11-07 The Cleveland Clinic Foundation Human factor vii deletion constructs for treating cancer

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5033352A (en) 1989-01-19 1991-07-23 Yamaha Corporation Electronic musical instrument with frequency modulation
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
JP3330932B2 (ja) * 1990-01-29 2002-10-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 抗凝固剤タンパク質
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US20040087498A1 (en) * 1991-02-28 2004-05-06 Novo Nordisk Health Care Ag Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
CA2280700A1 (en) 1997-02-14 1998-08-20 American Red Cross Expression of active human factor ix in mammary tissue of transgenic animals
US20050032690A1 (en) * 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
WO1999051773A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
DE19937219A1 (de) 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie
WO2001032711A2 (en) 1999-10-21 2001-05-10 Board Of Trustees Of The University Of Arkansas Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
PL206148B1 (pl) * 2000-02-11 2010-07-30 Bayer HealthCare LLCBayer HealthCare LLC Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
WO2001083725A1 (en) 2000-05-03 2001-11-08 Novo Nordisk A/S Human coagulation factor vii variants
US6905683B2 (en) * 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
EP1282438B1 (en) * 2000-05-10 2005-08-03 Novo Nordisk Health Care AG Use of pharmaceutical composition comprising a factor viia and a factor xiii
CN100475959C (zh) * 2000-09-13 2009-04-08 诺沃挪第克健康护理股份公司 人凝血因子vii变体
JP4361728B2 (ja) 2000-09-13 2009-11-11 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固因子ｖｉｉ変異型
IL154879A0 (en) * 2000-10-02 2003-10-31 Novo Nordisk As Factor vii glycoforms
US7173000B2 (en) * 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
CA2434139C (en) 2001-01-23 2014-05-27 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
US7235638B2 (en) * 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
AU2002249096B2 (en) 2001-03-22 2007-06-28 Novo Nordisk Health Care Ag Coagulation factor VII derivatives
AU2002315525A1 (en) * 2001-07-03 2003-01-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US6882883B2 (en) * 2001-08-31 2005-04-19 Medtronic, Inc. Implantable medical device (IMD) system configurable to subject a patient to a stress test and to detect myocardial ischemia within the patient
US7052868B2 (en) * 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
PL368619A1 (en) 2001-09-27 2005-04-04 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
WO2003029442A1 (en) * 2001-10-02 2003-04-10 Novo Nordisk Health Care Ag Method for production of recombinant proteins in eukaryote cells
US20030143219A1 (en) * 2001-10-09 2003-07-31 Madison Edwin L Nucleic acid molecules encoding a transmembrane serine protease 25, the encoded polypeptides and methods based thereon
JP3862996B2 (ja) 2001-10-31 2006-12-27 帝人ファイバー株式会社 ポリトリメチレンテレフタレートフィラメント糸およびその製造方法
US6960657B2 (en) * 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
WO2003044179A2 (en) * 2001-11-20 2003-05-30 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
EP1458407A1 (en) * 2001-12-21 2004-09-22 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
RU2004134726A (ru) 2002-04-30 2005-06-10 Максиджен Холдингз Лтд. (Ky) Варианты полипептида фактора vii или viia
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
WO2004005471A2 (en) * 2002-07-02 2004-01-15 Dendreon Corporation Serine protease 16
ES2293088T3 (es) 2002-09-25 2008-03-16 Novo Nordisk Health Care Ag Polipeptidos del factor vii de la coagulacion humana.
US6911323B2 (en) * 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
CA2840692A1 (en) 2002-09-30 2004-04-08 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
JP5376747B2 (ja) * 2002-10-02 2013-12-25 カタリスト バイオサイエンシーズ， インコーポレイテッド 改変された特異性を有するプロテアーゼを作製する方法およびスクリーニングする方法
CA2519873C (en) * 2003-03-20 2012-12-18 Maxygen Holdings Ltd. Fvii or fviia variants
FI20030413A7 (fi) 2003-03-20 2004-09-21 Suomen Intech Oy Kaasulaakerointi
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
US20040235054A1 (en) 2003-03-28 2004-11-25 The Regents Of The University Of California Novel encoding method for "one-bead one-compound" combinatorial libraries
CA2528239A1 (en) 2003-06-05 2004-12-16 Canadian Blood Services Mutants of the factor vii epidermal growth factor domain
US20060116324A1 (en) * 2003-06-13 2006-06-01 Novo Nordisk Healthcare A/G Novel formulations
ATE458057T1 (de) * 2003-06-19 2010-03-15 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne
ES2381110T3 (es) * 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
WO2005032581A2 (en) * 2003-10-07 2005-04-14 Novo Nordisk Health Care Ag Hybrid molecules having factor vii/viia activity
US20070072271A1 (en) * 2004-01-07 2007-03-29 Novo Nordisk Healthcare A/G Method for the production of recombinant proteins
WO2005075635A2 (en) 2004-02-03 2005-08-18 Novo Nordisk Health Care Ag Coagulation factor vii/viia variants lacking a functional lipid membrane binding domain
WO2005110453A2 (en) * 2004-04-12 2005-11-24 Catalyst Biosciences, Inc. Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
EP1761630A2 (en) * 2004-06-21 2007-03-14 Novo Nordisk Health Care AG Glycosylation-disrupted factor vii variants
WO2006014253A2 (en) * 2004-07-02 2006-02-09 Genentech, Inc. Factor viia variants
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
JP5690047B2 (ja) * 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
US20090011992A1 (en) * 2005-09-21 2009-01-08 Novo Nordisk Healthcare A/G Human Coagulation Factor VII Polypeptides
ES2611608T3 (es) * 2005-10-21 2017-05-09 Catalyst Biosciences, Inc. Proteasas modificadas que inhiben la activación del complemento
US8383388B2 (en) * 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
TWI369402B (en) * 2006-07-05 2012-08-01 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
BRPI0810172A2 (pt) * 2007-04-13 2014-10-14 Catalyst Biosciences Inc Polipeptídeos de fator vii modificado e seus usos
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
WO2010151736A1 (en) * 2009-06-25 2010-12-29 The University Of North Carolina At Chapel Hill Chimeric factor vii molecules
TWI595004B (zh) * 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
WO2014018120A1 (en) * 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof

Also Published As

Publication number Publication date
PL2147096T3 (pl) 2015-08-31
SV2009003393A (es) 2010-04-30
RU2571931C2 (ru) 2015-12-27
EP2147096B1 (en) 2015-03-25
DK2147096T3 (da) 2015-06-15
MX2009010997A (es) 2009-11-02
EP2147096A2 (en) 2010-01-27
PH12014501960A1 (en) 2015-10-19
ECSP099735A (es) 2010-01-29
JP2014042523A (ja) 2014-03-13
CN101743309B (zh) 2014-01-29
CN101743309A (zh) 2010-06-16
HK1134520A1 (en) 2010-04-30
UA101155C2 (ru) 2013-03-11
CN103451172A (zh) 2013-12-18
RU2009141510A (ru) 2011-05-20
NZ579985A (en) 2012-02-24
SG174077A1 (en) 2011-09-29
BRPI0810172A2 (pt) 2014-10-14
ZA201109181B (en) 2012-08-29
US20100166729A9 (en) 2010-07-01
CR11058A (es) 2010-02-09
NZ593611A (en) 2012-06-29
JP2010523150A (ja) 2010-07-15
IL201173A0 (en) 2011-08-01
ES2537328T3 (es) 2015-06-05
CA2683443A1 (en) 2008-10-23
CO6231052A2 (es) 2010-12-20
GT200900268A (es) 2015-03-25
SI2147096T1 (sl) 2015-07-31
AU2008239586A1 (en) 2008-10-23
JP5761782B2 (ja) 2015-08-12
US20090098103A1 (en) 2009-04-16
WO2008127702A3 (en) 2009-03-19
HN2009002098A (es) 2012-03-12
PT2147096E (pt) 2015-07-21
ZA200906854B (en) 2012-03-28
NI200900187A (es) 2010-10-11
WO2008127702A2 (en) 2008-10-23
EP2481797A1 (en) 2012-08-01
KR20150067772A (ko) 2015-06-18
IL218776A0 (en) 2012-05-31
JP2016155836A (ja) 2016-09-01
AU2008239586B2 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
KR101623602B1 (ko) 변형된 제ⅶ 인자 폴리펩티드 및 그의 용도
KR20100016462A (ko) 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도
AU2013204377B2 (en) Modified factor vii polypeptides and uses thereof
HK1134520B (en) Modified factor vii polypeptides and uses thereof
HK1174059A (en) Modified factor vii polypeptides and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091111

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130401

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141224

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150106

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150603

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151028

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160225

PC1904 Unpaid initial registration fee